How do I know if my Endometrial Cancer has an actionable mutation

Understanding Actionable Mutations in Endometrial Cancer

Great question—this is one of the most important things to understand about your diagnosis. Let me explain what "actionable" means and how doctors determine if your cancer has one.

What Makes a Mutation "Actionable"?

An actionable mutation is a specific genetic change in your cancer cells that doctors can target with a particular treatment. Think of it like having a lock (the mutation) and a key (the targeted drug)—if your cancer has the lock, the key might work better than standard chemotherapy.

According to NCCN Guidelines for Endometrial Cancer, there are four major molecular subtypes that doctors look for, and some are more actionable than others:

The Four Molecular Subtypes:

1. POLE-mutated - Usually has a good prognosis; these tumors often respond well to treatment
2. MSI-H (Microsatellite Instability-High) or dMMR (mismatch repair deficient) - Intermediate prognosis; may have sensitivity to certain immunotherapies
3. p53 aberrant (mutant) - The most aggressive subtype; requires multimodality treatment, especially chemotherapy
4. NSMP (No Specific Molecular Profile) - Wild-type p53; copy number-low

How Doctors Test for These Mutations

According to NCCN Guidelines, your pathology report should include testing for:

• POLE mutations - Sequencing of the exonuclease domain
• MMR/MSI status - Immunohistochemistry (IHC) or molecular testing to check for mismatch repair deficiency
• p53 expression - IHC staining to look for abnormal p53 patterns
• HER2 testing - Recommended for all p53 aberrant cancers
• ER/PR testing - Estrogen and progesterone receptor status (especially important for stage III, IV, or recurrent disease)

For metastatic or recurrent disease, doctors may also consider:

• NTRK gene fusion testing
• RET gene fusion testing
• Tumor Mutational Burden (TMB) testing

What This Means for Treatment

NCCN Guidelines emphasize that these molecular profiles may respond to therapy differently, which means:

• Some mutations may allow doctors to escalate (intensify) treatment
• Others may allow doctors to de-escalate (reduce) treatment while maintaining effectiveness
• Certain mutations open doors to targeted therapies or immunotherapies that work better than standard chemotherapy alone

Questions to Ask Your Doctor

To find out if YOUR cancer has actionable mutations, ask:

1. "Has my tumor been tested for POLE mutations, MSI/MMR status, and p53 expression?"
2. "What molecular subtype does my cancer fall into, and what does that mean for my treatment options?"
3. "Are there any targeted therapies or clinical trials available based on my specific mutations?"
4. "Should I have HER2, ER/PR, or other biomarker testing done?"
5. "Can I get a copy of my complete pathology report with all molecular testing results?"

Important Note

NCCN Guidelines strongly encourage comprehensive molecular profiling using FDA-approved assays or validated tests performed in CLIA-certified laboratories. The decision to do this testing depends on your center's resources and multidisciplinary team, but it's increasingly becoming standard of care.

If your initial pathology report doesn't include these molecular tests, ask your oncologist whether they should be performed—especially if you have high-risk features or advanced-stage disease.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.